Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushen Yiqi formula is a Traditional Chinese Medicine (TCM) herbal composition developed by researchers at Huashan Hospital, Fudan University. It is specifically designed to treat Chronic Obstructive Pulmonary Disease (COPD), particularly in patients presenting with the TCM syndrome of "deficiency of both lung and kidney." The formula typically contains herbs intended to tonify the lung and kidney systems, such as *Astragalus membranaceus* (Huangqi) and *Epimedium brevicornu* (Yinyanghuo), though specific ingredients can vary in "modified" versions. In clinical trials, it is evaluated as an adjunctive therapy to standard Western medicine (such as bronchodilators) to improve lung function, reduce the frequency of acute exacerbations, and enhance the quality of life for COPD patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bushen yiqi formula.